Innovative Bispecific Nanobody Targeting EGFR and ERBB2 for Next-Generation Cancer Therapy
VHH-P838 is a humanized bispecific nanobody designed to simultaneously target epidermal growth factor receptor (EGFR) and erb-b2 receptor tyrosine kinase 2 (ERBB2). Engineered as a fusion protein that combines two single-domain antibodies, VHH-P838 offers selective and potent binding to these clinically validated receptors implicated in multiple cancer types. Currently in the Biological Testing stage, this program aims to address key challenges in targeted cancer therapy by leveraging the advantages of nanobody architecture for improved tumor penetration. With the ability to recognize both EGFR and ERBB2, VHH-P838 holds significant promise for the treatment of a broad spectrum of malignancies driven by these pathways.
| Candidate | VHH-P838 |
| Target | epidermal growth factor receptor (EGFR) erb-b2 receptor tyrosine kinase 2 (ERBB2) |
| Modality | humanized bispecific VHH |
| Indication | Cancer |
Licensing Opportunity
VHH-P838 is available for out-licensing and collaborative development partnerships. We welcome inquiries from pharmaceutical and biotechnology companies interested in advancing innovative bispecific antibody therapeutics in oncology.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P838 |
Modality
VHH-P838 features a bispecific antibody fusion format, comprising two single-domain nanobodies—one against EGFR and one against a receptor tyrosine kinase—linked and further conjugated to rhamnose via a tris-polyethylene glycol linker. This modular and low-molecular-weight structure confers enhanced tissue penetration and superior molecular stability, key attributes for targeting cancers with dense tumor microenvironments. Nanobodies are renowned for their high solubility, ease of engineering, and robust expression in various systems. By uniting dual targeting in a compact and flexible molecule, VHH-P838 is primed to disrupt multiple signaling axes in tumors, potentially reducing resistance and improving clinical outcomes in cancer.
Target
EGFR and ERBB2 are both transmembrane receptor tyrosine kinases essential for cellular growth, survival, and differentiation. EGFR is predominantly expressed in epithelial tissues and is frequently dysregulated in cancers such as non-small cell lung, colorectal, and head and neck carcinomas. ERBB2, widely present in breast, gastric, and several other cancers, is well-known for driving aggressive tumor phenotypes when overexpressed or amplified. Both EGFR and ERBB2 act as central nodes in oncogenic signaling networks, making them prime therapeutic targets. VHH-P838’s capability to engage both EGFR and ERBB2 addresses tumor heterogeneity and mechanisms of resistance. Strategically, dual targeting expands the utility of this program across diverse cancer subtypes and reinforces its attractiveness in the precision oncology landscape.
Mechanism of Action
VHH-P838 exerts its effects through bispecific inhibition of EGFR and ERBB2, modulating proliferative signal transduction pathways central to cancer cell survival. By simultaneously binding to and blocking EGFR and ERBB2, this nanobody disrupts ligand-induced receptor dimerization and downstream oncogenic signaling cascades. The inhibition of these pathways can suppress cancer cell proliferation, induce apoptosis, and enhance sensitivity to other treatment modalities. The platform’s modular design opens opportunities for further engineering, such as integration into antibody-drug conjugates (ADC) or combination with immune effectors. As a next-generation signal transduction modulator, VHH-P838 embodies the flexible and innovative nature of nanobody-based oncology therapeutics.
Cancer
Cancer encompasses a diverse group of diseases characterized by uncontrolled cellular proliferation and the potential for invasion or metastasis. Cancers remain one of the leading causes of death globally, with millions of new diagnoses each year and high societal and economic burden. Current standard-of-care approaches include surgery, chemotherapy, radiation, immunotherapy, and targeted agents; however, response rates can be heterogeneous and long-term survival for many aggressive cancers remains limited. Resistance mechanisms and adverse effects often hinder efficacy. Unmet needs include therapies with improved specificity, reduced toxicity, and effective action against tumors exhibiting molecular heterogeneity or resistance to single-target agents. VHH-P838, by targeting both EGFR and ERBB2, aims to overcome tumor escape pathways and broaden therapeutic impact, addressing critical gaps in existing cancer treatments and offering new hope for patients with refractory disease.